Titre du document / Document title

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features : An open label study

Auteur(s) / Author(s)

AKKAYA Cengiz ; SIVRIOGLU Enver Yusuf ; AKGOZ Semra ; EKER Salih Saygin ; KIRLI Selcuk ;

Résumé / Abstract

Objective The aim of this study was to compare the efficacy and tolerability of reboxetine in the treatment of major depressive disorder (MDD) and MDD with anxiety features to venlafaxine XR. Method Patients with MDD, aging 18 between 65 years, were randomly allocated to two groups receiving either open-label venlafaxine XR capsules (n=50) or reboxetine tablets (n=43). Subjects were administered Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Scale (HAM-A) at baseline and 2, 4, 7, 10 weeks after the baseline visit. Results Response rates to antidepressant treatment were significantly higher in the venlafaxine XR group at 10th week. When patients having anxious depression were analysed separately; response rate for anxiety of reboxetine group was significantly higher at 7th week only. Mean number of side effects were significantly higher in reboxetine group. Only one subject in each group was dropped out due to side effect. Conclusion We may suggest that reboxetine is as effective and tolerable as venlafaxine XR in the treatment of MDD and MDD with anxiety features, and it may be considered a treatment option to venlafaxine XR.

Revue / Journal Title

Human psychopharmacology   ISSN 0885-6222   CODEN HUPSEC 

Source / Source

2006, vol. 21, n^o5, pp. 337-345 [9 page(s) (article)]

Langue / Language

Anglais

Editeur / Publisher

Wiley, Chichester, ROYAUME-UNI  (1986) (Revue)

Mots-clés d'auteur / Author Keywords

venlafaxine ; reboxetine ; depression ; anxiety ; depression with anxiety features ; treatment ;

Localisation / Location

INIST-CNRS, Cote INIST : 21186, 35400013901591.0070